Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Research and Innovation Action · Running

ExoCordOA EV-enriched secretome from cord blood as a new disease modifying treatment for osteoarthritis

Coordinator
Exogenus Therapeutics SA, Portugal
Runs
1 September 2026 to 31 August 2031
Status
Running
EU funding
€13.0m
Total cost
€13.0m
Partners
10 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101288259

What the project is doing

In the project's own words, from its summary on CORDIS.

ExoCordOA is a flagship initiative to advance secretome-based therapies through two complementary pillars: (1) the clinical development of Exo-101 for osteoarthritis (OA), and (2) the resolution of systemic bottlenecks that limit broader adoption of secretome medicines. Exo-101, a first-in-class extracellular vesicle (EV)-enriched secretome derived from umbilical cord blood, has demonstrated robust anti-inflammatory, immunomodulatory, and regenerative effects in preclinical models of OA.

ExoCordOA will advance Exo-101 GMP-manufacturing, GLP preclinical safety validation, and all the regulatory and clinical activities needed to finalise Phase I and II clinical trials during the project lifetime. Ultimately, this project will advance Exo-101 towards Phase III post-project, potentially positioning it as Europe’s first clinically validated secretome therapy for OA. In parallel, the project addresses the systemic bottlenecks that hinder broad adoption of EV-based medicines.

It will establish a GMP-compliant manufacturing process, develop integrated quality control combining AI-enhanced optical fingerprinting with multi-omics profiling, and support implementation of clinically relevant potency assays based on deep EV characterization in biological fluids. Furthermore, by convening a regulatory forum of international experts, ExoCordOA will provide an evidence-based framework to inform future approvals of secretome therapies.

Bringing together biotech innovators, clinical trial experts, hospitals, CROs, GMP manufacturers, regulators, academics, a cord blood bank, market experts and patient representatives, the consortium has the expertise and infrastructure to deliver a disease-modifying treatment for OA while building the foundations for Europe’s leadership in secretome-based therapeutics.

Topics

Who is involved

OrganisationCityCountryRole
Exogenus Therapeutics SACantanhedePortugalCoordinator
Academisch Ziekenhuis MaastrichtMaastrichtNetherlandsParticipant
Lonza Netherlands BVMaastrichtNetherlandsParticipant
Stichting ReumaNederlandAmsterdamNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Universiteit UtrechtUtrechtNetherlandsParticipant
Ilof - Intelligent Lab on Fiber, Unipessoal LdaMatosinhosPortugalParticipant
Anthony NolanLondonUnited KingdomParticipant
Eliquent Life Sciences, U.K., Ltd.CamberleyUnited KingdomParticipant
Image Analysis LimitedLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI